Syneron Medical Ltd. (ELOS) announced the commercial launch of the elure topical skin whitening products in several Asian markets. The company will sell these products through its dermatologists, beauty salons and spas in Asia from the first quarter of 2010.
The elure skin whitening product is an enzymatic skin whitening treatment that targets and decomposes melanin to reveal a visibly lighter and exceptionally luminous skin tone. The product uses a naturally occurring bio-active substance, Melanozyme, which decomposes the melanin in a fast and safe manner with no side effects.
In the process, Melanozyme is combined with a bio-activator to diminish the dark colored pigment in the skin. The use of Melanozyme eliminates side effects such as skin redness and burning sensation which are seen in the case of other skin whitening products available in the market.
It has been estimated that skin whitening is one of the fastest growing segments of the global beauty industry. The global whitening market is expected to grow over 10% annually. In particular, the Asian market is estimated to be roughly $18 billion per annum in size and is expected to grow rapidly.
Headquartered in Yokneam Illit, Israel, Syneron Medical was founded in 2000 and is engaged in the design, development, and marketing of aesthetic medical products based on its proprietary electro-optical synergy (ELOS) technology. Its medical aesthetic devices are powered by proprietary software, and use the combined-energy technology of bi-polar radio frequency (RF) and optical energy (laser or non-coherent light).
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Syneron Medical Ltd. (ELOS) announced the commercial launch of the elure topical skin whitening products in several Asian markets. The company will sell these products through its dermatologists, beauty salons and spas in Asia from the first quarter of 2010.
The elure skin whitening product is an enzymatic skin whitening treatment that targets and decomposes melanin [...]
Syneron Medical Ltd. (ELOS) announced the commercial launch of the elure topical skin whitening products in several Asian markets. The company will sell these products through its dermatologists, beauty salons and spas in Asia from the first quarter of 2010.
The elure skin whitening product is an enzymatic skin whitening treatment that targets and decomposes melanin to reveal a visibly lighter and exceptionally luminous skin tone. The product uses a naturally occurring bio-active substance, Melanozyme, which decomposes the melanin in a fast and safe manner with no side effects.
In the process, Melanozyme is combined with a bio-activator to diminish the dark colored pigment in the skin. The use of Melanozyme eliminates side effects such as skin redness and burning sensation which are seen in the case of other skin whitening products available in the market.
It has been estimated that skin whitening is one of the fastest growing segments of the global beauty industry. The global whitening market is expected to grow over 10% annually. In particular, the Asian market is estimated to be roughly $18 billion per annum in size and is expected to grow rapidly.
Headquartered in Yokneam Illit, Israel, Syneron Medical was founded in 2000 and is engaged in the design, development, and marketing of aesthetic medical products based on its proprietary electro-optical synergy (ELOS) technology. Its medical aesthetic devices are powered by proprietary software, and use the combined-energy technology of bi-polar radio frequency (RF) and optical energy (laser or non-coherent light).
Syneron Medical Ltd. (ELOS) is set to acquire Primaeva Medical, Inc., an aesthetic technology firm based in Pleasanton, CA. The acquisition is expected to close before the end of 2009. Per the agreement, Syneron will acquire Primaeva for $7 million in cash and up to $23 million of additional payment based on the achievement [...]
Yesterday, Syneron Medical Ltd (ELOS) announced that it would buy Candela Corp. (CLZR) in a $65 million all-stock transaction. The merger is expected to be completed by year-end.
It was agreed that Candela stockholders would receive 0.2911 ordinary shares of Syneron for each share of Candela. 6.7 million shares will be issued by Syneron for the [...]
The healthcare stocks remained in focus on Wednesday ahead of President Obama’s speech tonight on his healthcare reform effort. The healthcare space also witnessed heightened activity amid a flurry of corporate news.[More...]
All News |
Breaking News |
Featured Stories